Catalyst Pharmaceutical Partners Inc Stock
A loss of -1.580% shows a downward development for Catalyst Pharmaceutical Partners Inc.
Catalyst Pharmaceutical Partners Inc is currently one of the favorites of our community with 11 Buy predictions and no Sell predictions.
As a result the target price of 24 € shows a very positive potential of 62.77% compared to the current price of 14.75 € for Catalyst Pharmaceutical Partners Inc.
For the coming years our community has positive and negative things to say abot the Catalyst Pharmaceutical Partners Inc stock. Criterium "Revenue growth" gathered the most positive votes but regarding "Worthwhile Investment for the next years" there were negative voices in the community.
Pros and Cons of Catalyst Pharmaceutical Partners Inc in the next few years
Pros
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
S********** s********
?
G***** c******* t* c**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Catalyst Pharmaceutical Partners Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Catalyst Pharmaceutical Partners Inc | -1.580% | -2.221% | 7.081% | 31.476% | -5.116% | 221.102% | 369.287% |
| Ardelyx Inc. | -3.980% | -3.853% | 15.454% | 108.097% | 19.170% | 20.842% | - |
| Evolus Inc | -5.830% | 2.564% | 13.208% | 34.078% | 32.597% | 61.074% | - |
| Salarius Pharmaceuticals Inc. | 5.580% | 3.141% | -10.860% | -67.167% | -29.009% | -98.470% | -99.993% |
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.
Last updated at 2023-04-16
Catalyst Pharma (CPRX) appears to be fundamentally improving its financial position, owing to the growth seen in recent financial statements. Observing the company's financials, the trend of increasing revenues, net income, total assets, and shareholder's equity is noticeable. This indicates that Catalyst Pharma has been experiencing a growth phase in its business operations in the market.
*Pros: *
Revenue Growth: The company is experiencing substantial growth in total revenue from 2020 to 2022, which is positive for its financial position. This revenue growth is attributed to the company's ability to successfully market and sell its products, positively reflecting its business operations.
Comments
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its price target raised by analysts at HC Wainwright from $24.00 to $26.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $29.00 price target on the stock.
Show more
Ratings data for CPRX provided by MarketBeat
Catalyst Pharmaceuticals, Inc. (NASDAQ: CPRX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $34.00 price target on the stock.
Show more
Ratings data for CPRX provided by MarketBeat